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AA Homozygous wildtype genotype 
Aa     Heterozygous variant genotype 
Aa Homozygous variant genotype 
AFAP  Attenuated familial adenomatous polyposis 
APC Adenomatous polyposis coli 
ATP5a1 ATP synthase gene 
BER Base excision repair 
Cdk4    Cyclin dependent kinase 4 
CHRPE        Congenital hypertrophy of the retinal pigment 
CK1 Casein kinase 1 
CK2 Casein kinase 2 
c-Myc v-myc myelocytomatosis viral oncogene homolog 
(avian) 
CRC  Colorectal cancer 
CRAC1 Colorectal adenoma and carcinoma 1 
DNA  Deoxyribonucleic acid 
EIF3H Eukaryotic translation initiation factor 3, 
subunit H 
EDTA  Ethylenediaminetetraacetic acid 
FAP  Familial adenomatous polyposis 
GI Gastro intestinal 
GREM1 Gremlin 1, cysteine knot superfamily,  
homolog (Xenopus laevis) 
GSK3β  Glycogen synthase-3β kinase 
G382D Glycine at position 382 replaced with aspartate 
HNPCC Hereditary non-polyposis colorectal cancer 
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LEF/TCF Lymphoid enchancer-binding factor 1/ 
T cell specific transcription factor 
LOC120376;FLJ45803 Hypothetical protein LOC120376;FLJ45803 protein 
LOH  Loss of heterozygosity 
MAP  MYH-associated polyposis 
MCR  Mutation cluster region 
Min  Multiple intestinal neoplasia 
MMR Mismatch repair  
Mom  Modifiers of Min 
MUTYH MutY human homologue 
MYH  MutY human homologue 
NER Nucleotide excision repair 
NHEJ Non-homologous end joining  
PCR   Polymerase chain reaction 
POU5F1P1  POU class 5 homeobox 1 pseudogene 1 
RT-PCR Real time polymerase chain reaction 
SMAD7  SMAD family member 7 
SNP  Single nucleotide polymorphism 
SPSS  Statistical Package for the Social Sciences 
Y165C Tyrosine at position 165 replaced with cysteine 
 
     
       
                            
     








Background: Familial adenomatous polyposis (FAP) is a hereditary autosomal dominant 
condition characterized by the appearance of hundreds to thousands of adenomatous 
polyps throughout the colon and rectum. If the condition is left untreated it will 
ultimately develop into colorectal cancer.  Most of the articles available today concerning 
FAP focus on the adenomatous polyposis coli gene as this gene appears to be the most 
frequent mutated gene in FAP patients. Recent studies suggest that certain modifier genes 
may play an important role in the development of colorectal cancer in the general 
population this may also be true for FAP. 
 
Aim of the study: The aim of this study was to examine 199 Australian APC mutation 
positive FAP patients with a molecular diagnosis of FAP for polymorphisms in five loci 
on chromosomes 10p14, 8q23.3, 8q24, 11q23, 18q21 and the gene ATP5a1.  
 
Methods: The genotypes were determined for each individual by finding the 
polymorphic combination for the candidate single nucleotide polymorphisms (SNPs). 
When a genotype was determined for a particular DNA sample, the nucleotide present at 
the polymorpic site was reported. The results were analysed using statistical programs.  
 
Results: The result of this study revealed that there is an increased risk of developing 
polyps if a patient harbours the heterozygote or variant genotype of the SNP rs10318 
compared to patients with the wildtype genotype. This appears to be a protective effect 
against early polyp development in FAP individuals who harbours the variant genotype 
of SNP rs3802842 compared with those with a wildtype or heterozygote genotype. 
Patients harbouring the variant genotype of the SNP rs4779584 have an increased risk of 




Conclusion: In conclusions the findings from this study indicate that modifier genes have 
an effect on disease expression in FAP patients. These results warrant further 
investigation in larger FAP populations that harbour APC mutations to confirm the 
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1 - INTRODUCTION 
 
1.1 Colorectal cancer 
 
Colorectal cancer (CRC) is one of the most common and preventable forms of cancer 
worldwide, accounting for more than 100,000 deaths the United States in 2008 [1]. 
Several genetic and environmental factors contribute to the development of cancer and it 
is estimated that up to 35% of all colorectal cancers are caused by a genetic 
predisposition [2]. During the years of research several high penetrance alleles have been 
identified [3]. These include alleles causing Familial Adenomatous Polyposis (FAP), 
Hereditary Non-polyposis Colorectal Cancer (HNPCC/Lynch syndrome), Peutz Jeghers 
syndrome and Juvenile polyposis. Genetic testing is available for these conditions and 
there are different protocols for how the patients and their families should be treated [2].  
The focus of this thesis is on the condition FAP which accounts for approximately 1% of 
all colorectal cancers [4].  
 
1.2 Familial Adenomatous Polyposis  
 
Familial adenomatous polyposis (FAP) is a hereditary autosomal-dominant condition 
characterized by the appearance of hundreds to thousands of adenomatous polyps 
throughout the colon and rectum [4]. Manifestation outside the colon occurs frequently 
and include Gardner’s syndrome, congenital hypertrophy of the retinal pigment 
epithelium, hepatoblastoma, fundic gland polyps in the stomach, pancreas and thyroid, 
dental abnormalities and malignant tumours in the central nervous system [4, 5]. If left 
untreated the condition will ultimately develop into colorectal cancer [4]. However, the 
risk of developing cancer is generally considered to be related to polyp number, with 
more polyps leading to a higher risk of developing cancer [4].  
 
The incidence of FAP in the population is approximately 1 in 8000 and the polyps 
usually appear by adolescence or third decade of life [5]. Adenocarcinomas occur 10-20 
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years after the polyps have developed and the majority of the carcinomas are found on 
the left side of the intestine [5].    
 
Genetic testing is important for FAP patients seeing as the vertical transmission through 
generations is very likely due to the condition’s autosomal dominant inheritance pattern 
with high penetrance [2]. Patients with the following characteristics should be tested [2]: 
1) Individuals with some but not all the features of classical FAP. 2) Individuals who 
manifest clinically defined FAP, but where the mutation has not been defined within the 
family (up to 25% of FAP cases come from de novo APC mutations and these patients 
will have no family history of the disease). 3) Relatives within an FAP cohort family 
once the founder mutation is known.  
 
When a patient presents with colonic polyps, there is a strong recommendation to have an 
annual colonoscopy from adolescence considering the high risk of developing colorectal 
cancer which is often followed by prophylactic colectomy or proctolectomy [4].  
 
1.3 Attenuated Familial Adenomatous polyposis   
 
Attenuated familial adenomatous polyposis (AFAP) is a milder form of FAP where there 
is a later diagnosis of polyps (>50 years), fewer polyps (5-100), more frequent 
localization in the proximal colon and fewer extracolonic manifestations  [2, 5]. APC 
germline mutations are found in 20-30% of patients with AFAP and the mutations are 
often located at the proximal or distal parts in exon 9 of the APC gene [6].   
 
The frequency of upper gastro intestinal (GI) polyposis and other features of AFAP are 
similar compared to classical FAP [6]. Depending on the age of onset of colorectal cancer 
in a AFAP family, surveillance may be initiated later than in families with classical FAP 
[6]. Colonoscopy is usually offered by the age of 15 [6].  
 
 12
AFAP patients carry a significant increased risk of developing colorectal cancer and is 
sometimes mistaken for sporadic cases of colorectal cancer or hereditary non-polyposis 
colorectal cancer (HNPCC) [5].   
 
1.4 Extracolonic manifestations   
 
Extracolonic manifestations occur in approximately 70% of FAP patients [7]. It still 
remains to be determined whether the manifestations can be related to the location of the 
mutations in the APC gene [7]. The different extracolonic manifestations include 
Gardner’s syndrome, desmoids disease, congenital hypertrophy of the retinal pigment 
epithelium, hepatoblastoma, fundic gland polyps in the stomach, pancreas and thyroid, 
dental abnormalities and malignant tumours in the central nervous system [4, 5, 8, 
9].Gardner’s syndrome is a condition where the colonic polyps are associated with 
epidermoid skin cysts and benign osteoid tumours of the mandible and long bones and is 
very common in cases of FAP [5]. Desmoid disease are rare benign and invasive 
firbromatoses [8]. They appear in 10% of FAP patients and are prone to local invasions 
and recurrence but tend not to metastasize [8]. Congenital hypertrophy of the retinal 
pigment epithelium (CHRPE) occur in ~60% of FAP families [4]. The condition can be 
detected by opthalmoscopy at any age and is therefore a good technique to use to identify 
at-risk families before the polyps have appeared [4]. CHRPE is a condition without 
malignant potential which does not affect the patient’s sight [4]. FAP patients also have a 
significantly increased risk of hepatoblastoma, fundic gland polyps in the stomach, 
pancreas and thyroid, dental abnormalities and malignant tumours in the central nervous 
system known as Turcot’s syndrome [4, 10]. 
 
1.5 The genes involved in the development of FAP 
 
The genes known to be involved in the development of FAP include the adenomatous 
polyposis coli (APC) and the MutY homolog (MYTYH) genes [4]. However, recent 
studies suggest that certain modifier genes may also play an important role in the 
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development of CRC [11-13]. Most of the literature concerning FAP focuses on the APC 
gene as this gene is the most frequent mutated gene in FAP patients. Research show that 
16% of the APC-mutation-negative FAP patients have a mutation in the MUTYH gene 
[14]. 
 
Several articles recently published focus on modifier genes and the effect they have on 
development of CRC [11-13]. Another recent study show that the gene known as ATP5a1 
may act as a modifier gene in the development of colorectal cancer [15]. Since these 
recent findings do not address the condition known as FAP the main focus of this thesis 
will be on establishing whether the polymorphisms in five loci on chromosomes 10p14, 
8q23.3, 8q24, 11q23, 18q21 and the gene ATP5a1 may have an influence on the 
development of FAP and CRC.  
 
1.5.1 The Adenomatous Polyposis Coli gene  
 
FAP is caused by a germline mutation in the tumour suppressor gene adenomatous 
polyposis coli (APC) on chromosome 5q21-22 [16]. Most of the germline mutations are 
nonsense or frameshift mutations and result in a truncated protein product with abnormal 
functions [4].  
 
According to Knudson’s two-hit hypothesis, FAP patients develop somatic APC 
mutations or loss of heterozygosity (LOH) in addition to the original germline mutation 
they carry [4]. The site of the “first hit” which is the germline mutation seems to 
determine the “second hit” which is the somatic mutation in both FAP and sporadic cases 
of CRC [17]. 
 
There is a phenotype-genotype correlation occurring in APC positive FAP patients [4]. 
Polyp number in FAP patients appears to depend on the location of the mutation in the 
APC gene [16]. However, this is still uncertain as there are many factors contributing to 
the development of colorectal cancer [4]. Generally, germline mutations located between 
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codons 450 and 1600 result in a more stable truncated protein. These mutations seem to 
be associated with a higher number of polyps [18].  
 
The APC gene consist of 8535 base pair organized into 21 exons [4]. Most of the 
germline and somatic APC mutations occur in exon 15. More than 50% occur between 
codons 1286 and 1513 [19]. This region is known as the mutation cluster region (MCR) 
[19]. Since this region is frequently affected by mutations, it is one of the first areas in the 
APC gene that are searched in when new families are tested for APC mutations (see 
figure 1.1)  [5]. APC mutations in the MCR region seems to be associated with LOH, 
while mutations that are not in the MCR, seem to be associated with protein truncating 




Figure 1.1 Domains present on the APC gene. The mutation cluster region can be seen from 
codon 1286 to 1513 and is a hot spot for mutations in the APC gene (figure adapted from 
Narayan and Roy [10]).  
 
 
As one of the earliest events in the multi-step development of colorectal cancer, the APC 
gene mutation plays an important role in cell growth and migration, signal transduction, 
and control of chromosome stability [10]. APC regulates β-catenin levels through Wnt-
signaling, thus the Wnt-signaling pathway plays an important role in the development of 
colorectal cancer [10].  
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The Wnt signaling pathway (figure 1.2) is important in organ development, cellular 
proliferation, morphology, motility, and embryogenesis [10].  APC seems to down 
regulate  β-catenin through the Wnt-signaling pathway [10]. β-catenin signals in the 
transformation of colonic epithelial cells and in melanoma progression and is believed to 
be the main partner of APC in its tumour suppression function [10, 19].  
 
β-catenin levels are normally low in the cytoplasm through proteasome-mediated 
degradation [20]. This degradation is controlled by a complex containing axin 
(Axil/conduction), APC, and glycogen synthase-3β kinase (GSK3β). When cells receive 
Wnt signals, the GSK3β is inhibited from phosphorylating the β-catenin, APC and Axin 
complex, thus β-catenin accumulates in the cytoplasm and nucleus [10, 20].  
β-catenin in the nucleus will interact with transcription factors such as lymphoid 
enhancer-binding factor 1/T cell specific transcription factor (LEF/TCF) and affect the 
transcription [20]. Consequently, if there is a mutation of β-catenin or truncation of APC, 
the stability and transcriptional activity of β-catenin increases [10]. Due to the increased 
cell proliferation in the colonic epithelial cells adenomatous lesions will appear [20].  
 
Recent observations suggest that colon tumours carrying mutations in the APC gene also 
have increased levels of c-Myc, a proto-oncogene important in cellular proliferation [10, 
21]. C-Myc seem to primarily function as a transcriptional regulator and is involved in 
numerous critical processes including apoptosis, proliferation, cell metabolism, DNA 
repair, and angiogenesis [21].   
C-Myc also functions as a transcriptional repressor of genes involved in cell adhesion and 
growth arrest. Recent data even suggest that c-Myc might play a direct role in DNA 
replication [21]. When c-Myc is increased through the Wnt-signaling pathway, the 
expression of cyclin dependent kinase 4 (Cdk4) gene is up-regulated. The Cdk4 gene 




Figure 1.2 A model of the Wnt-signaling pathway. Figure A shows the normal colonic epithelial 
cell. In the absence of Wnt-signaling, GSK3β and CK1 or 2 kinases become active and 
phosphorylate β-catenin [10].  
Figure B shows the colon cancer cell. There is an increased level of β-catenin due to the mutation 
in APC gene or β-catenin (figure adapted from Narayan and Roy. [10]). 
 
1.5.2 MutY human homologue gene  
 
Thousands of DNA lesions are repaired every day by different DNA repair systems that 
have overlapping specificities [22]. At present, approximately 150 DNA repair gene 
products have been identified [22, 23]. There appears to be 5 major repair pathways: 1) 
base excision repair (BER), 2) mismatch repair (MMR) 3) nucleotide excision repair 
(NER) 4) homologous recombination (HR) and 5) non-homologous end joining (NHEJ) 
[24]. The five repair mechanisms function together to protect DNA from environmental 
attack and keep normal cellular metabolism to maintain genome integrity [24]. 
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MutY human homologue (MUTYH) gene is a base excision repair gene playing an 
important role in the process of repairing DNA damage caused by reactive oxygen 
species [14]. If the MUTYH protein is dysfunctional, mutations in the APC gene may 
occur, the most frequent mutations being G:C→T:A transversions [25]. The MUTYH 
gene is located on chromosome 1 between p32.1 and p34.3 [25]. There are two hot spot  
mutations responsible for 80% of the mutations in the MUTYH gene, Y165C and G382D 
[6].  Research show that 10-20% of patients with APC-mutation-negative FAP and AFAP 
harbour a bialleic mutation in the MUTYH gene [6]. This condition is called MYH-
associated polyposis (MAP) and can be difficult to distinguish from classical FAP and 
AFAP because of the similar phenotype [6].) After excluding APC gene mutations in 
FAP patients by genetic testing, MUTYH germline mutation testing is indicated [6].  
Approximately 50% of patients with MUTYH gene mutations develop colorectal cancer 
[25]. 
 
1.6 Single Nucleotide Polymorphisms  
 
Single nucleotide polymorphisms (SNPs) are mutations involving a single DNA base 
substitution observed with a frequency of 1% or more in a given population [26, 27]. 
SNPs account for 90% of the inter-individual variability, and occurs approximately every 
100-300 basepair in the general human population [26, 28]. This frequency makes for 
100 000 amino acid differences in humans and most SNPs are inherited from one 
generation to the next [26]. The fact that SNPs may alter the genetic sequence in an 
inherited gene makes it a useful and accessible tool to perform family-based association 
studies [26]. 
 
1.7 Association studies 
 
Association studies are a good way to establish a correlation between a region of the 
genome, SNPs and a disease [26]. By knowing the genomic position of a SNP and 
identifying it in a population one is able to determine an association to a phenotypic 
characteristic [27]. 
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The frequency of a disease trait (i.e. SNP) is determined by comparing two groups that 
differ for the presence of the phenotype [26].  One of the groups will have a disease trait 
and the other group will either be known to be unaffected or chosen randomly from the 
population [27].  
 
Association studies may be performed with a carefully pre-selected group of patients 
harbouring candidate genes previously linked to the disease [27]. By using a population 
known to have a genomic linkage to the disease one may be able to focus on biologically 
defined candidate genes, genes suggested by differential display experiments, or 
positional candidates from prior linkage investigations [27].     
 
1.7.1 Modifier genes 
 
Modifier genes change the phenotypic expression caused by a mutation in another gene 
[15]. Tumour modifier genes can be important in cancer development by either 
enhancing or suppressing the initiation, growth and/or progression of tumour cells [15].  
 
There are many factors influencing genes and the development of colorectal cancer, 
making it difficult to study cancer development in humans due to environmental factors 
[29]. When studying purely the way genes influence the development of disease, animal 
models might be more suitable considering there are no unforeseen environmental factors 
affecting the results [29]. The study of Multiple Intestinal Neoplasia (min) mice is a good 
example of the way animal models can be used to study cancer development and modifier 
genes [15]. The mice harbour a germline APC mutation and have been used to study the 
mutation in the modifier gene ATP synthase (ATP5a1) [15]. 
 
1.7.2 The ATP synthase gene 
 
A recent study performed at the Thomas Jefferson University showed some interesting 
results concerning the modifier gene called ATP synthase (ATP5a1) [15] The study 
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revealed that the ATP5a1 gene suppresses colorectal cancer in mice when it is mutated 
[15]. Mice harbouring one copy of the mutated gene had a reduction in small intestinal 
and colon polyps by approximately 90% [15]. The Min mice used in the study carry 
germline mutations in the APC gene and this is regarded as the murine version of the 
human FAP condition [15, 29].  The results from the study implied that the ATP5a1 gene 
only suppresses the tumour cells when it is present on the same chromosome as the 
variant APC gene (in mice they are both present on chromosome 18) [15]. However, 
ATP5a1 is present on chromosome 18 in humans, APC is present on chromosome 5q21-
22 [15, 16].  
 
The ATP5a1 gene encodes the α-subunit of ATP synthase, a multi-subunit enzyme which 
resides on the mitochondrial membrane [29]. If the ATP5a1 gene is absent this will lead 
to a non-functioning α synthase subunit, thus leading to apoptosis of the cell [29].  
 
1.7.3 The candidate SNPs 
 
The pathways involved in the control of the genome are complex and not well 
understood, especially considering the difficulties in disease loci identification. One way 
to map out the genes involved in disease is the candidate gene approach [30]. The 
candidate gene approach generally requires a large number of patients, which essentially 
have nothing in common except that they have the disease, and controls to create enough 
statistical power to identify an association with disease [30]. This approach is best suited 
for detecting genes with a minor influence on disease risk and an understanding of the 
mechanism underlying the disease studied are necessary [30]. 
Recent studies have revealed that the SNPs rs16892766, rs3802842, rs10318, rs4939827, 
rs4464148, rs6983267, rs7014346, rs4779584 and rs10795668 are related to an increased 
risk of CRC [11-13].  
 
A study of SNP rs16892766 located on chromosome 8q23.3 of the gene EIF3H, SNP 
rs10795668 located on chromosome 10p14 of an unidentified gene, SNP rs6983267 
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located on chromosome 8q24.21 of an unidentified gene and SNP rs4939827 located on 
chromosome 18q21.1 of the gene SMAD7 found that there is a correlation between the 
SNPs and the risk of developing CRC [13].  
 
Another study concerning SNP rs4779584 located on chromosome 15 located in between 
SCG5 and GREM1, and SNP rs10318 located on chromosome 15 near the gene GREM1 
were significantly associated with CRC [11]. GREM1 encodes a secreted bone 
morphogenetic protein (BMP) antagonist and it is possible that the gene may increase 
tumour proliferation [11].  
 
Finally, a study of SNP rs7014346 located on chromosome 8q24 near the gene 
POU5F1P1, SNP rs3802842 located on chromosome 11 near the gene 
LOC120376:FLJ45803 and SNP rs4939827 located on chromosome 18q21 of the gene 












































2 – AIM OF THE STUDY 
 
The aim of this study is to examine 199 Australian APC mutation positive FAP patients 
with a molecular diagnosis of FAP for polymorphisms in five loci on chromosomes 
10p14, 8q23.3, 8q24, 11q23, 18q21 and the gene ATP5a1. This will involve assaying 9 
polymorphisms in the loci described above and 18 polymorphisms in the ATP5a1 gene 




































































3.1.1 Study population 
 
This study consisted of 199 FAP patients with germline APC mutations confirmed 
through molecular diagnostics of blood-extracted DNA. Out of the 199 patients, 148 was 
affected with polyps of which 80 developed CRC (see table 3.1). The data used in this 
study was collected from the Hunter Area Pathology Services (HAPS), John Hunter 
Hospital, Newcastle, New South Wales, Australia between the years 1997 and 2008.  
 
A database was compiled with the following patient details; laboratory number, date of 
birth, gender, gene, exon, nucleotide change, consequence of mutation, polyps, age of 
diagnosis of polyposis/age unaffected, colorectal cancer, age of diagnosis of cancer/age 
unaffected, other symptoms, family cancer and consent. The form used to collect the 
patient details is shown in Appendix 1. 
 
All the patients participating in the study had given informed written consent prior to the 
study. Ethics approval was obtained from the Human Research Ethics Committee, 
University of Newcastle and the Hunter New England, Newcastle, New South Wales, 
Australia.  
 
Table 3.1 The samples divided into groups according to disease expression.  
Group Sample size (n) 
Subject group (all samples) 199 
Affected with polyps 148 
Affected with CRC 80 
Unaffected with polyps 51 
Unaffected with CRC 119 
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3.1.2 Reagents, materials and equipment 
 
The reagents, materials and equipment used in the study are listed in table 3.2-3.5.  
 
Table 3.2 A list of the reagents used in the study.  
Reagents Concentration Supplier 
TaqMan® Universal PCR Master Mix 2 x Applied Biosystems* 
TaqMan®, SNP Genotyping Assays, Pre-Designed, 
SMALL-Scale 40 x Applied Biosystems* 
 
*Applied Biosystems, Foster City, CA, USA. 
 
Table 3.3 A list of the materials used in the study. 
Materials Supplier 
96-well PCR Microplate Axygen® Scientific* 
96-well Masterblock® plate Greiner Bio-One ** 
 
* Axygen® Scientific, Union City, CA, USA. 
** Greiner Bio-One, Frickenhausen, Germany.  
 
Table 3.4 A list of the equipment used in the study. 
Equipment Supplier 
7500 Real-Time PCR System Applied Biosystems* 
GeneAmp® PCR System 9700 Applied Biosystems* 
 







Table 3.5 A list of the reagents used in the PCR setup.   
Reagents Volume in 1 reaction (μL) 
TaqMan® Universal PCR Master Mix 2.5 




DNA (50 ηg/μL) 1 
Total volume into each well 5 
 
3.1.3 DNA isolation 
 
The genomic DNA used in the study was obtained from Molecular Genetics, Hunter Area 
Pathology Services, John Hunter Hospital, Newcastle, New South Wales, Australia. The 
DNA had previously been extracted from 10 ml EDTA blood using the “salting-out” 




This study is an association study which aims to identify genetic polymorphisms that can 
be used to predict disease expression in individuals who are already known to be at risk 
of developing colorectal cancer. This risk is due a highly penetrant mutation in a gene 
known to be associated with colorectal cancer risk.  
The genotypes were determined for each individual by finding the polymorphic 
combination for the 9 candidate SNPs in the five loci previously described. Three 
variable genotypes for every polymorphism were possible; homozygote wildtype (AA), 
heterozygote variant (Aa) or homozygote variant (aa). When a genotype was determined 
for a particular DNA sample, the nucleotide present at the polymorphism site was 
reported, i.e. in the gene SMAD7 (polymorphism rs4939827) was expressed as CC for 
the homozygote wildtype, CT for heterozygote and TT for homozygote variant.  
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The genotype frequency distribution for the 18 SNPs in the gene ATP5a1 was performed 
at the Australian Genome Research facility laboratory however due to insufficient time 
and cost effectiveness, but the results did not arrive before this thesis was due to be 
submitted.   
 
3.2.1 The principle behind Real-time PCR system 
 
The genomic DNA in this study was analysed using TaqMan ® SNP Genotyping Assays 
on a 7500 Real-Time PCR System and a GeneAmp® PCR 9700 System, all from Applied 
Biosystems.   
 
Real-time PCR follows the general principle of the polymerase chain reaction. The 
difference from the traditional PCR system is the ability to monitor the PCR process as it 
occurs. DNA is quantified in real-time after each amplification cycle and the data is 
collected throughout the process rather than at the end of the PCR [32] .  
A PCR reaction mix is used in the process. The assay contains primers to amplify a 
specific nucleic acid sequence and a reagent to detect and quantify the amplified target 
[33]. In this study the real-time PCR system is used to detect certain SNPs in a patients 
DNA. The SNPs are detected by using fluorogenic 5’nuclease assay (see figure 3.1). A 5’ 
reporter dye and a 3’ quencher dye are covalently linked to the probes. During the PCR 
extension phase, the 5’ reporter dye is cleaved by the nuclease activity of the TaqMan 
polymerase which leads to an increase in the characteristic fluorescence of the reporter 
dye (see figure 3.1) By quantifying and comparing the fluorescence signals it is possible 
to determine the allelic content of each sample on the plate (see figure 3.2) [32]. The 
fluorescence is induced by light distributed from an argonion laser excitation source to all 
sample wells. The fluorescence is then directed to a charge couplet device camera which 
detects the amount of fluorescence. With every cycle the fluorescence intensity will 







Figure 3.1 The figure illustrates how the probe is required to match the target sequence 
in order to become fluorescent. If the SNP is present this causes a mismatch in one of the 
probes and the sample does not become fluorescent (Figure reproduced with permission 
of Applied Biosystems (see appendix II) [33]). 
 
3.2.2 Molecular analysis 
 
All the SNPs used in this study were purchased from Applied Biosystems, Foster City, 
CA, USA (see table 3.2.1 and 3.2.2). Before analysing the DNA, a preliminary test was 
conducted to confirm the accuracy of the assays and if the reaction conditions for the 
real-time PCR were optimal. After a successful preliminary test, sample analysis was 
carried out on a 96-well optical reaction plate (Axygen Scientific). Each reaction 
contained 2.5 μL TaqMan® Universal PCR Master Mix, 0.125 μL TaqMan® SNP 
Genotyping Assay, 1.375 μL distilled water and 1 μL DNA (50 ηg/μL), with a final 
reaction volume of 5 μL. For every SNP, a positive control for wild type, heterozygote 
and/or variant genotype was provided. The plate also contained at least two negative 
water controls without any DNA.  
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All the wells were assigned to individual samples making it possible to identify the DNA 
samples as one of the different genotypes after the PCR and allelic discrimination had 
been performed. The PCR reaction was conducted on an ABI PRISM 7500 Real-Time 
PCR system or a GeneAmp® 9700 PCR System from Applied Biosystems. PCRs 
performed on the GeneAmp® PCR System 9700 had to be followed by an allelic 
discrimination on the 7500 Real-Time PCR system. The following thermal cycling 
condition was used: two initial holds at 50 °C for 2 minutes and 95 °C for 10 minutes 
followed by 60 cycles of 92 °C for 15 seconds and 60 °C for 1 minute.  
After each PCR, an allelic discrimination was performed (see figure 3.2). If there were 
uncertainties about which genotype group a sample DNA belonged in due to inefficient 
amount of fluorescence, the sample would have to be re-analysed. If the sample persisted 
to give a poor amplified signal, the sample was taken out of the study for the SNP in 




Figure 3.2 This picture shows the results from an allelic discrimination displayed in a graph. The 
software automatically group samples in clusters according to genotype. The diamonds represent 
a variant genotype sample, the triangles represent a heterozygote genotype sample and the circles 
represent a wildtype genotype sample. The two squares further down in the picture represent the 












Table 3.2.1 TaqMan®, SNP Genotyping Assays, Pre-Designed, SMALL-Scale from Applied 
Biosystems*.  
Gene** Chromosome Assay ID Polymorphism (SNP) Genotype 
EIF3H 8 C_32670283_10 rs16892766 A>C 
LOC120376;FLJ45803*** 11 C_27503482_10 rs3802842 A>C 
GREM1 15 C_12070332_20 rs10318 C>T 
SMAD7 18 C_27913406_10 rs4939827 C>T 
SMAD7 18 C_27989234_10 rs4464148 T>C 
 18 C_29086771_10 rs6983267 T>G 
POU5F1P1 8 C_29086780_10 rs7014346 G>A 
SCG5, GREM1 15 C_28019826_10 rs4779584 C>T 
 10 C_1779559_10 rs10795668 G>A 
 
* Applied Biosystems, Foster City, CA, USA. 
** The gene the polymorphism has been linked to.  
*** Locus on chromosome. 
 
Table 3.2.2 Table showing the context sequence for the SNPs used in the study.  
Polymorphism 
















rs6983267: Forward GTCCTTTGAGCTCAGCAGATGAAAG[G/T]CACTGAGAAAAGTACAAAGAATTTT 
rs7014346: Forward TCAAGATGGCTTCTGGAGTGCTACC[A/G]TTACATCCATGTTGTAGGCTAGAAG 
rs4779584: Reverse AGAACTTGTTGATAAGCCATTCTTC[C/T]GAACAGAAACCATAACTATACACAC  
rs10795668: Reverse AGAAAGAGAAAAAGTTAGATTCTTA[A/G]ATTCCATGATTTTATATTTCCCACC 
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3.2.3 Statistical Analysis 
 
The statistical analysis was performed on the software package SPSS Version 12.0. 
Statistical analysis was conducted to establish whether certain SNPs segregate alone or 
together, with specific disease expression in FAP patients with an APC mutation. 
Person’s chi-square (χ2) test was performed to assess genotype frequency distribution for 
the different subject groups. If more than 1/5 of the groups to be compared contained less 
than 5 patients, a Fisher’s exact test was performed. Significance of the results were 
accepted if p<0.05. Odds ratios (OR) and condifidence intervals (CI) were calculated for 
the groups with significant results.  
 
Kaplan-Meier curves were used to establish differences in age of diagnosis/age 
unaffected with polyps and CRC within the genotype groups for the different candidate 
SNPs. In this study Log rank, Breslow and Tarone-Ware were tested for every Kaplan-
Meier curve. The log-rank test, which emphasizes observations from later ages, the 
Breslow test, which gives more weight to early ages and the Tarone-Ware test that is 
intermediate of the two other tests, was used to examine the homogeneity of the Kaplan-
Meier survival curves. The Kaplan-Meier curves that are significantly different will be 

































































4 - RESULTS  
 
4.1 Genotype frequency distribution in APC mutation positive 
FAP patients 
 
The genotype frequency distribution for the different SNPs in this study was determined 
to establish a correlation with disease development in FAP patients. All the patients in the 
study had a confirmed germline APC mutation. For analysis the total population of 
patients were sub-divided into groups according to the following: 
 Female vs. male patients.    
 Affected with polyps vs. unaffected with polyps. 
 Affected with CRC vs. unaffected with CRC.   
In addition to wildtype, heterozygote and variant genotype, a combination of the 
genotypes were tested for genotype frequency distribution. The wildtype genotype was 
tested in a combination with heterozygote genotype against variant genotype. In addition 
wildtype genotype was tested against a combination of heterozygote genotype and variant 
genotype. This was done to establish whether the polymorphism was either a dominant or 
recessive modifier of disease risk.    
 
Table 4.1 The table shows the different SNPs and states whether a significant difference in the 
sub-divided groups and in the Kaplan-Meier graphs was identified. It does, however, not state the 
genotypes for the significant differences found (for this information go to table 4.2-4.10 and 
figure 4.1-4.3). 
 
SNP Gender Polyps CRC 
Age of diagnosis/age 
unaffected with polyps 
Age of diagnosis/age 
unaffected with CRC 
rs10318 No Yes No No No 
rs16892766 No No No No No 
rs3802842 No No No Yes No 
rs4939827 No No No No No 
rs4464148 No No No No No 
rs6983267 No No No No No 
rs7014346 No No No No No 
rs4779584 No No No Yes Yes 
rs10795668 No No No No No 
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4.1.1 SNP rs10318 
 
For the rs10318 SNP a significant difference was observed when comparing the three 
different genotypes for the patients affected with or unaffected with polyps (p=0.012). In 
addition, another significant difference was found when comparing the wildtype 
genotype with the combination of heterozygote and variant genotype (CC versus CT+TT) 
in patients affected with or unaffected with polyps (p=0.005). Therefore, patients affected 
with heterozygote or variant genotype has an increased risk of developing polyps (OR 
2.61 (1.33-5.15), p=0.006) (see table 4.2).  
 
Table 4.2 Study demographics of the SNP rs10318 in APC mutation positive FAP patients 























(n=196) 102 (52) 73 (37) 21 (11)  175 (89)  94 (48)  
         
Female (n=105) 59 (56) 32 (31) 14 (13) 91 (87) 46 (44) 
Male (n=91) 43 (47) 41 (45) 7 (8) 
 





         
Polyps+ (n=145) 66 (46) 60 (41) 19 (13) 126 (87) 79 (54) 
Polyps- (n=51) 35 (69) 14 (27) 2 (4) 
 
p=0.012 49 (96) 
 




       2OR=2.61    CI=1.33-5.15            p=0.006 
CRC+ (n=78) 36 (46) 31 (40) 11 (14) 67 (86) 42 (54) 
CRC- (n=118) 65 (55) 43 (36) 10 (9) 
 
p=0.325 108 (91) 
 
p=0.212 53 (45) 
 
p=0.221 
         
1Comparison of genotype frequencies using Pearson’s Chi-square. 
2OR is the relative risk of developing polyps for a patient with heterozygote or variant genotype relative to 
patients with the wildtype genotype.  
3Comparison of genotype frequency using Fisher’s exact test. 
Note: affected with polyps (polyps+), unaffected with polyps (polyps-), affected with 







4.1.2 SNP rs16892766, rs3802842, rs4939827, rs4464148, rs6983267, 
rs7014346, rs4779584 and rs10795668 
 
The genotype frequency distribution for the SNPs rs16892766, rs3802842, rs4939827, 
rs4464148, rs6983267, rs7014346, rs4779584 and rs10795668 did not reveal any 
statistically significant association within the different sub-groups analysed (see table 
4.3-4.10).  
 
Table 4.3 Study demographics of the SNP rs16892766 in APC mutation positive FAP patients 





























2 (1)  
 
194 (99)  
 
21 (11)  
         
Female (n=105) 94 (89) 10 (10) 1 (1) 104 (99) 11 (11) 
Male (n=91) 81 (89) 9 (10) 1 (1) 
 
p=1.0 90 (99) 
 
p=1.0 10 (11) 
 
p=0.908 
         
Polyps+ (n=145) 132 (91) 11 (8) 2 (1) 143 (99) 13 (9) 
Polyps- (n=51) 42 (82) 9 (18) 0 (0) 
 
p=0.121 51 (100) 
 
p=1.0 9 (18) 
 
p=0.091 
         
CRC+ (n=79) 71 (90) 7 (9) 1 (1) 78 (99) 8 (10) 
CRC- (n=117) 103 (88) 13 (11) 1 (1) 
 
p=0.908 116 (99) 
 
p=1.0 14 (12) 
 
p=0.689 
         
1Comparison of genotype frequency using Fisher’s exact test. 
2Comparison of genotype frequencies using Pearson’s Chi-square. 
Note: affected with polyps (polyps+), unaffected with polyps (polyps-), affected with colorectal cancer 

















Table 4.4 Study demographics of the SNP rs3802842 in APC mutation positive FAP patients 
according to disease expression and gender. 
 











(n=196) 85 (43) 88 (45) 23 (12) 
 
173 (88)  111 (57) 
 
         
Female (n=105) 52 (50) 40 (38) 13 (12) 92 (88) 53 (50) 
Male (n=91) 33 (36) 48 (53) 10 (11) 
 
p=0.111 81 (89) 
 
p=0.793 58 (64) 
 
p=0.062 
         
Polyps+ (n=145) 65 (45) 64 (44) 16 (11) 129 (89) 80 (55) 
Polyps- (n=51) 20 (39) 24 (47) 7 (14) 
 
p=0.749 44 (86) 
 
p=0.608 31 (61) 
 
p=0.487 
         
CRC+ (n=78) 35 (45) 34 (44) 9 (11) 69 (89) 43 (55) 
CRC- (n=118) 50 (42) 54 (46) 14 (12) 
 
p=0.941 104 (88) 
 
p=0.945 68 (58) 
 
p=0.730 
         
1Comparison of genotype frequencies using Pearson’s Chi-square. 
Note: affected with polyps (polyps+), unaffected with polyps (polyps-), affected with colorectal cancer 
(CRC+) and unaffected with colorectal cancer (CRC-). 
 
 
Table 4.5 Study demographics of the SNP rs4939827 in APC mutation positive FAP patients 























(n=198) 55 (28) 94 (47) 49 (25)  149 (75)  143 (72)  
         
Female (n=106) 30 (28) 50 (47) 26 (25) 80 (75) 76 (72) 
Male (n=92) 25 (27) 44 (48) 23 (25) 
 
p=0.984 69 (75) 
 
p=0.939 67 (73) 
 
p=0.860 
         
Polyps+ (n=147) 41 (28) 70 (48) 36 (24) 111 (76) 106 (72) 
Polyps- (n=51) 15 (29) 23 (45) 13 (26) 
 
p=0.952 38 (75) 
 
p=0.887 36 (71) 
 
p=0.835 
         
CRC+ (n=80) 23 (29) 35 (44) 22 (27) 58 (73) 57 (71) 
CRC- (n=118) 33 (28) 58 (49) 27 (23) 
 
p=0.699 91 (77) 
 
p=0.460 85 (72) 
 
p=0.904 
         
1Comparison of genotype frequencies using Pearson’s Chi-square. 
Note: affected with polyps (polyps+), unaffected with polyps (polyps-), affected with colorectal cancer 




Table 4.6 Study demographics of the SNP rs4464148 in APC mutation positive FAP patients 























(n=197) 98 (500 81 (41) 18 (9)  179 (91)  99 (50)  
         
Female (n=105) 55 (52) 41 (39) 9 (9) 96 (91) 50 (48) 
Male (n=92) 43 (47) 40 (43) 9 (10) 
 
p=0.731 83 (90) 
 
p=0.768 49 (53) 
 
p=0.429 
         
Polyps+ (n=146) 71 (49) 63 (43) 12 (8) 134 (92) 75 (51) 
Polyps- (n=51) 27 (53) 18 (35) 6 (12) 
 
p=0.541 45 (88) 
 
p=0.449 24 (47) 
 
p=0.596 
         
CRC+ (n=79) 40 (51) 35 (44) 4 (50 75 (95) 39 (49) 
CRC- (n=118) 58 (49) 46 (39) 14 (12) 
 
p=0.254 104 (88) 
 
p=0.104 60 (51) 
 
p=0.839 
         
1Comparison of genotype frequencies using Pearson’s Chi-square. 
Note: affected with polyps (polyps+), unaffected with polyps (polyps-), affected with colorectal cancer 
(CRC+) and unaffected with colorectal cancer (CRC-). 
 
  
Table 4.7 Study demographics of the SNP rs6983267 in APC mutation positive FAP patients 























(n=197) 55(28) 82 (42) 60 (30) 
 
137 (70)  142 (72) 
 
         
Female (n=106) 25 (24) 45 (42) 36 (34) 70 (66) 81 (76) 
Male (n=91) 30 (33) 37 (41) 24 (26) 
 
p=0.285 67 (74) 
 
p=0.249 61 (67) 
 
p=0.143 
         
Polyps+ (n=146) 40 (27) 59 (41) 47 (32) 99 (68) 106 (73) 
Polyps- (n=51) 15 (29) 23 (45) 13 (26) 
 
p=0.666 38 (74) 
 
p=0.371 36 (71) 
 
p=0.777 
         
CRC+ (n=79) 23 (29) 33 (42) 23 (29) 56 (71) 56 (71) 
CRC- (n=118) 31 (26) 50 (43) 37 (31) 
 
p=0.895 81 (69) 
 
p=0.738 87 (74) 
 
p=0.661 
         
1Comparison of genotype frequencies using Pearson’s Chi-square. 
Note: affected with polyps (polyps+), unaffected with polyps (polyps-), affected with colorectal cancer 





Table 4.8 Study demographics of the SNP rs7014346 in APC mutation positive FAP patients 























(n=198) 79 (40) 84 (42) 35 (18)  163 (82)  119 (60)  
         
Female (n=106) 36 (34) 49 (46) 21 (20) 85 (80) 70 (66) 
Male (n=92) 43 (47) 35 (38) 14 (15) 
 
p=0.184 78 (85) 
 
p=0.398 49 (53) 
 
p=0.067 
         
Polyps+ (n=147) 55 (38) 65 (44) 27 (18) 120 (82) 92 (62) 
Polyps- (n=51) 24 (47) 19 (37) 8 (16) 
 
p=0.480 43 (84) 
 
p=0.665 27 (53) 
 
p=0.226 
 OR=        
CRC+ (n=80) 32 (40) 36 (45) 12 (15) 68 (85) 48 (60) 
CRC- (n=118) 47 (40) 48 (41) 23 (19) 
 
p=0.686 95 (81) 
 
p=0.416 71 (60) 
 
p=0.981 
         
1Comparison of genotype frequencies using Pearson’s Chi-square. 
Note: affected with polyps (polyps+), unaffected with polyps  
(polyps-), affected with colorectal cancer (CRC+) and unaffected with colorectal cancer (CRC-). 
 
 
Table 4.9 Study demographics of the SNP rs4779584 in APC mutation positive FAP patients 























(n=198) 127 (64) 53 (27) 18 (9)  180 (91)  71 (36)  
         
Female (n=106) 67 (63) 27 (26) 12 (11) 94 (83) 39 (37) 
Male (n=92) 60 (65) 26 (28) 6 (7) 
 
p=0.491 86 (93) 
 
p=0.241 32 (35) 
 
p=0.769 
         
Polyps+ (n=147) 93 (63) 40 (27) 14 (10) 133 (90) 54 (37) 
Polyps- (n=51) 33 (65) 14 (27) 4 (8) 
 
p=0.937 47 (92) 
 
p=0.719 18 (35) 
 
p=0.854 
         
CRC+ (n=80) 53 (66) 19 (24) 8 (10) 72 (90) 27 (34) 
CRC- (n=118) 73 (62) 35 (30) 10 (8) 
 
p=0.645 108 (92) 
 
p=0.714 45 (38) 
 
p=0.529 
         
1Comparison of genotype frequencies using Pearson’s Chi-square. 
Note: affected with polyps (polyps+), unaffected with polyps  




Table 4.10 Study demographics of the SNP rs10795668 in APC mutation positive FAP patients 























(n=197) 86 (44) 83 (42) 28 (14)  169 (86)  111 (56)  
         
Female (n=106) 46 (43) 47 (45) 13 (12) 93 (88) 60 (57) 
Male (n=91) 40 (44) 36 (40) 15 (16) 
 
p=0.643 76 (84) 
 
p=0.398 51 (56) 
 
p=0.937 
         
Polyps+ (n=146) 61 (42) 64 (44) 21 (14) 125 (86) 85 (58) 
Polyps- (n=51) 25 (49) 18 (35) 8 (16) 
 
p=0.560 43 (84) 
 
p=0.821 26 (51) 
 
p=0.370 
         
CRC+ (n=79) 29 (37) 38 (48) 12 (15) 67 (85) 50 (63) 
CRC- (n=118) 56 (47) 45 (39) 17 (14) 
 
p=0.301 101 (86) 
 
p=0.879 62 (53) 
 
p=0.135 
         
1Comparison of genotype frequencies using Pearson’s Chi-square. 
Note: affected with polyps (polyps+), unaffected with polyps  
(polyps-), affected with colorectal cancer (CRC+) and unaffected with colorectal cancer (CRC-). 
 
4.2 Kaplan-Meier survival analysis 
 
Kaplan-Meier survival analysis showed that there was a significant difference between 
the age of diagnosis and genotypes for SNP rs3802842 and rs4779584. For SNP 
rs3802842 there was a significant difference between the age of diagnosis of polyps and 
the combination of the wildtype and heterozygote genotypes compared with the variant 
genotype. For SNP rs4779584 there was a significant difference between the age of 
diagnosis for both polyps and CRC with the combination of the wildtype and 
heterozygote genotypes compared with variant genotype. 
4.2.1 SNP rs3802842 
 
When studying the Kaplan-Meier graph for SNP rs3802842 patients with the wild type 
and heterozygous genotypes combined compared to the variant genotype had a 
significant difference in the age of developing polyps (see figure 4.1). The group with 
wildtype and heterozygote genotype contained 173 patients and the group with mutant 
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genotype contained 23 patients. The median age of diagnosis of polyps (age of which 
50% of the population is free of polyps) was 39 years for the combination of wildtype 
and heterozygote genotype and 57 years for the mutant genotype (table 4.10).  
 
 
Table 4.10 Median age of diagnosis of polyps (age of which 50% of the population is free of 
polyps) in APC positive FAP participants for the SNP rs3802842.  
 
Genotype Age of subject group1
Wildtype and heterozygote (AA+AC) 39 yrs (n=173) 
Variant (CC) 57 yrs (n=23) 
1Subject group includes 196 samples. 
 
 
Figure 4.1 Kaplan-Meier graph for SNP rs3802842 showing the distribution of age of 
diagnosis/age unaffected with polyps for patients with wildtype and heterozygote genotype vs. 
variant genotype (log-rank test: p=0.018, Breslow: p=0.049, Tarone-Ware: p=0.029).  
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4.2.2 SNP rs4779584 
 
When studying the Kaplan-Meier graph for SNP rs4779584, the combination of the wild 
type and heterozygous genotyped compared to the variant genotype was significantly 
different (see figure 4.2). The group with wildtype and heterozygote genotype contained 
180 patients and the group with mutant genotype contained 18 patients. The median age 
of diagnosis of polyps was 43 years for the combination of wildtype and heterozygote 
genotypes and 28 years for the mutant genotype (table 4.11).  
 
 
Table 4.11 Median age of diagnosis of polyps (age of which 50% of the population is free of 
polyps) in APC positive FAP participants for the SNP rs4779584.  
 
Genotype Age of subject group1
Wildtype and heterozygote (AA+AC) 43 yrs (n=180) 
Variant (CC) 28 yrs (n=18) 






Figure 4.2 Kaplan-Meier graph for SNP rs4779584 showing the distribution of age of 
diagnosis/age unaffected with polyps for patients with wildtype and heterozygote genotype vs. 
variant genotype (log-rank: 0.062, Breslow: 0.013, Tarone-Ware: 0.014). 
 
 
When studying the Kaplan-Meier graph for SNP rs4779584, the combination of the 
wildtype and heterozygous genotypes compared to the variant genotype was significantly 
different for the age of CRC development (see figure 4.3). The group with the wildtype 
and heterozygote genotype contained 180 patients and the group with mutant genotype 
contained 18 patients. The median age of diagnosis of polyps was 59 years for the 
combination of the wildtype and heterozygote genotypes and 44 years for the mutant 








Table 4.12 Median age of diagnosis of CRC (age of which 50% of the population is free of CRC) 
in APC positive FAP participants for the SNP rs4779584. 
 
 
Genotype Age of subject group1
Wildtype and heterozygote (CC+CT) 59 yrs (n=180) 
Variant (TT) 44 yrs (n=18) 
1Subject group includes 198 samples 
 
 
Figure 4.3 Kaplan-Meier graph for SNP rs4779584 showing the distribution of age of 
diagnosis/age unaffected with CRC for patients with wildtype and heterozygote genotype vs. 





4.2.3 SNP rs16892766, rs4939827, rs4464148, rs6983267, rs7014346, 
rs10795668 and rs10318 
 
No difference in genotype frequency was observed when the age of diagnosis of polyps 
or CRC was examined for SNP rs16892766, rs4939827, rs4464148, rs6983267, 


























5 – DISCUSSION 
 
Genetic variation is the foundation for the enormous diversity in the human phenotype, 
and consequently the huge range of susceptibilities to common diseases, especially 
cancer [34]. It is generally accepted that genomic instability is the hallmark of 
malignancy. Cancer is a disease of abnormal gene expression due to inactivation of 
negative mediators and activation of positive mediators of cell proliferation [35]. By 
studying genetic variation it is possible to demonstrate which changes are likely to result 
in disease [36]. When occurring within an entire gene that contains coding and non-
coding regions, single nucleotide polymorphisms (SNPs) have the potential to change 
protein function or its expression thereby directly contributing to disease variability 
observed in the expressed phenotype [37]. Association studies with polymorphisms in 
candidate genes that are likely to affect tumour development and progression are 
excellent for the purpose of identifying common genetic variants that lead to modest 
differences in disease risk [38]. It has been well established that the use of well defined 
study populations when using the candidate gene approach to search for genetic modifiers 
is an important testable approach that it is more likely to reveal true genetic associations 
between varitations in the genome and disease [39]. Genetic variation studies may not 
result in a clear understanding about the causative role of the identified genes, and are not 
always replicated in other studies [40]. This is most likely due to the fact that each 
genetic variant linked to complex diseases has only a modest effect on disease risk and 
does not adequately take into consideration gene-gene interactions yet alone gene-
environmental  factors that together contribute to disease risk [41].        
 
Familial adenomatous polyposis (FAP) affects 1 in 8000 and the condition accounts for 
approximately 1% of all CRC [5]. Most research performed on FAP up to this point has 
focused on the genes, APC and MUTYH, to determine their role in disease expression in 
patients with this disorder. As cancer development is known to be influenced by many 
genetic factors, it is important to explore the possibility of different genes being involved 
in the the expression of disease since persons harbouring identitcal mutations in APC or 
MUTYH can have very different disease profiles that can not be explained by 
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environmental factors alone. Modifier genes have been proposed to be involved in 
influencing disease expression in FAP patients [42-44]. A number of recent publications 
that have examined the whole human genome for SNPs involved in sporadic CRC and 
have identified a number of SNPs that are over-represented in the CRC population in 
comparison to a healthy control population. The functional significance of these SNPs are 
not known at present but they are markers that may be important in hereditary colorectal 
cancer predispositions, including FAP. Therefore, the aim of this study was to determine 
whether these SNPs influence the age of diagnosis of polyposis and/or CRC and the risk 
of developing polyps and CRC among FAP patients that harboured a germline APC 
mutation.  
 
A study by Jaeger et al. established an association between the SNP rs10318 and the risk 
of developing CRC [11]. Their study showed that the variant allele increased the risk of 
developing CRC. In concordance with this study, the results presented in the FAP 
population examined in this study indicate that there is an increased risk of developing 
polyps (OR 2.58, CI 1.33-5.15) if a patient harbours the heterozygote or variant genotype 
of SNP rs10318 compared to patients with the wildtype genotype. However, our results 
did not reveal an association for an altered risk of developing CRC and there was no 
significant difference observed for rs10318 and the age of diagnosis of polyps or CRC. 
The reason for this is likely to be due to FAP patients developing a pre-malignant 
phenotype relatively early in their lives, therefore these patients are a special group to 
evaluate differences in genotype frequency and CRC risk. The other more commonly 
inherited predisposition to CRC, hereditary non polyposis colorectal cancer (HNPCC) 
differs from FAP in that patients with HNPCC are identified when they present with 
disease whereas FAP patients initially present with polyps that are removed before the 
development of CRC. Consequently, the risk of developing CRC in a FAP population is 
considerably different from the most common genetic predisposition to CRC, HNPCC. 
For this significant reason, it is much more difficult to study CRC risk and differences in 
the phenotypic expression in FAP patients as many of them will have interventional 
surgery to reduce their risk of developing colorectal cancer. Nevertheless SNP rs10318 
which is linked to the gene GREM1 is thought to increase tumour proliferation [11] and 
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may therefore have a relationship with colonic crypt stem cell proliferation that 
culminates in adenoma formation.  
 
Results from this study have revealed that the rs3802842 SNP is protective for the early 
development of polyposis in FAP individuals who harbour the variant genotype 
compared to those carrying the wildtype or heterozygous genotypes. No significant 
differences were found for the rs3802842 SNP and altered risk of developing CRC or 
polyposis. An earlier study by Tenesa et al. examined the rs3802842 SNP which showed 
a significant difference in the risk of developing CRC in a European population [12]. 
However, no significant differences were observed in a Japanese population [12] 
although the trend of the results was similar. Differences between populations might be 
due to different environmental factors contributing to the differences in disease risk. 
Taken together, these results indicated that rs3802842 might be a marker of a population 
specific CRC susceptibility allele [12]. Together, our results and those of others suggest 
that this SNP is indeed an effect modifier as it appears to follow a similar pattern in 
different populations. 
 
In addition, the results of the current study suggest that patients harbouring the variant 
genotype of rs4779584 develop polyps and CRC at an earlier stage compared to patients 
harbouring the wildtype or heterozygote genotypes. There was, however, no significant 
difference in genotype frequency distribution for the risk of developing polyps or CRC. A 
previous study performed by Jaeger et al. suggests that there is a correlation between the 
variant allele of the SNP rs4779584 and the development of CRC [11]. This study 
provides evidence that this SNP may be important for the early presentation of a 
premalignant phenotype as well as progression to disease. Identification of individuals 
with the variant genotype is important for the implementation of screening strategies at 
an early age to remove premalignant polyps that are likely to cause disease development. 
 
The current study of a series of candidate SNPs has the potential to reveal modifiers of 
FAP disease expression in patients with APC mutations which will provide important 
information for patient management by determining individual risk of disease 
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development and to possibly implement personalised treatment, especially for those with 
early onset disease. If modifier genes influencing disease expression in FAP are 
confirmed and the number extended better preventative measures could be developed and 
implemented, leading to better patient outcomes for FAP patients who already have an 
increased risk of disease as they harbour an APC mutation. 
   
One of the limitations of the study is the size of the study population. To provide stronger 
statistical power to confirm the findings of this study, more patients with APC mutations 
are required in addition to performing this analysis in an independent cohort of FAP 
patients. Moreover, a larger group is also required for haplotype analysis as the 
combination of disease associated SNPs may have an additive effect on disease 
expression. Performing haplotype analysis, will improve our understanding of disease 
pathways to help identify patients at an altered risk of disease development. FAP patients 
have a pre-malignant phenotypic expression in the form of polyps which are removed if 
discovered. Since the polyps are removed it can be difficult to study the genotypic 
expression of CRC in FAP patients as many of them may never present with malignancy. 
This presents some challenges when studying the disease expression in FAP patients. 
Furthermore, additional studies are required to examine the number of polyps and 
possible candidate SNPs as increasing polyp number, increases disease risk.  
 
In conclusion, the findings of this study indicate that there is an increased risk of 
developing polyps for the patients harbouring the heterozygote or variant genotype of the 
rs10318 SNP. The variant genotype of SNP rs3802842 appears to have a protective effect 
for early polyp development in FAP individuals with APC mutations. Patients harbouring 
the variant genotype of the SNP rs4779584 have an increased risk of developing polyps 
and CRC at an earlier stage. Finally, this study has revealed a number of SNPs that 
possibly influence disease expression in APC mutation positive FAP patients. These 
findings give further insight into the molecular mechanisms involved in FAP and these 
SNPs may help to identify patients at an altered risk of developing disease so that the 
appropriate treatment can be implemented.   
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7 - APPENDIXES 
 
 
Appendix I:  The form used to collect patient details. 
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